title: Consumption of polyunsaturated fat improves the saturated fatty acid-mediated impairment of HDL antioxidant potential.
abstract: METHODS
  The present study aimed to compare the effects of diets containing high-fat, high-cholesterol and saturated fatty acids (HFHC-SFA) and HFHC-polyunsaturated fatty acids-containing (HFHC-PUFA) diets on two major antiatherogenic functions of HDL, the HDL antioxidant function and the macrophage-to-feces reverse cholesterol transport.
  
  
  RESULTS
  Experiments were carried out in mice fed a low-fat, low-cholesterol (LFLC) diet, an HFHC-SFA diet or an HFHC-PUFA diet in which SFAs were partly replaced with an alternative high-linoleic and α-linolenic fat source. The HFHC-SFA caused a significant increase in serum HDL cholesterol and phospholipids as well as elevated levels of oxidized HDL and oxidized LDL. Replacing SFA with PUFA significantly reduced the levels of these oxidized lipoproteins and enhanced the ability of HDL to protect LDL from oxidation. The SFA-mediated impairment of HDL antioxidant potential was not associated with the cholesterol content of the diet, obesity or insulin resistance. In contrast, the effect of the HFHC diets on fecal macrophage-derived cholesterol excretion was independent of the fatty acid source.
  
  
  CONCLUSIONS
  SFA intake impairs the antioxidant potential of HDL and increases serum levels of oxidized lipoprotein species whereas the antioxidant potential of HDL is enhanced after PUFA consumption.
authors.affiliation: Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Barcelona, Spain.|CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM Madrid, Spain.
authors.forename: Lídia
authors.initials: L
authors.lastname: Cedó
authors.affiliation: National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum, Helsinki, Finland.
authors.forename: Jari
authors.initials: J
authors.lastname: Metso
authors.affiliation: Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Barcelona, Spain.|CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM Madrid, Spain.
authors.forename: David
authors.initials: D
authors.lastname: Santos
authors.affiliation: Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Barcelona, Spain.|Departament de Bioquímica i Biología Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Jose Luís
authors.initials: JL
authors.lastname: Sánchez-Quesada
authors.affiliation: Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Barcelona, Spain.|CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM Madrid, Spain.|Departament de Bioquímica i Biología Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Josep
authors.initials: J
authors.lastname: Julve
authors.affiliation: Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Barcelona, Spain.
authors.forename: Annabel
authors.initials: A
authors.lastname: García-León
authors.affiliation: Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Barcelona, Spain.|Departament de Bioquímica i Biología Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Josefina
authors.initials: J
authors.lastname: Mora-Brugués
authors.affiliation: National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum, Helsinki, Finland.
authors.forename: Matti
authors.initials: M
authors.lastname: Jauhiainen
authors.affiliation: Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Barcelona, Spain.|CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM Madrid, Spain.|Departament de Bioquímica i Biología Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Francisco
authors.initials: F
authors.lastname: Blanco-Vaca
authors.affiliation: Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Barcelona, Spain.|CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM Madrid, Spain.|Departament de Bioquímica i Biología Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Joan Carles
authors.initials: JC
authors.lastname: Escolà-Gil
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000378:metabolism*; D002784:Cholesterol / Q000378:metabolism* / Q000494:pharmacology; D059305:Diet, High-Fat / Q000009:adverse effects*; D005227:Fatty Acids / Q000009:adverse effects / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology*; D005243:Feces; D007333:Insulin Resistance; D008075:Lipoproteins, HDL / Q000737:chemistry / Q000378:metabolism*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008810:Mice, Inbred C57BL; D010743:Phospholipids / Q000378:metabolism
chemical_list: D000975:Antioxidants; D005227:Fatty Acids; D005231:Fatty Acids, Unsaturated; D008075:Lipoproteins, HDL; D010743:Phospholipids; D002784:Cholesterol
keywords: HDL; Oxidation; Polyunsaturated fatty acids; Reverse cholesterol transport; Saturated fatty acids